• Home
  •  / Johnson & Johnson

Johnson & Johnson

OverviewSuggest Edit

Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field. The company operates in three business segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment is focused on the therapeutic areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolism, as well as pulmonary hypertension. The Medical Devices segment includes a range of products used in the orthopedic, surgery, interventional solutions, and eye health fields.

Its major brands include:

TypePublic
Founded1886
HQNew Brunswick, NJ, USMap
Websitejnj.com
Employee Ratings4.2More
Overall CultureC+More
View Jobs (5)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)132,200(-2%)
Job Openings5
Revenue (FY, 2019)$82.1 B
Share Price (Feb 2021)$163 (-1%)
Cybersecurity ratingCMore

Key People/Management at Johnson & Johnson

Alex Gorsky

Alex Gorsky

Chairman, Board of Directors and Chief Executive Officer
Joaquin Duato

Joaquin Duato

Vice Chairman of the Executive Committee
Peter Fasolo

Peter Fasolo

Executive Vice President, Chief Human Resources Officer
Ashley McEvoy

Ashley McEvoy

Executive Vice President, Worldwide Chairman, Medical Devices
Thibaut Mongon

Thibaut Mongon

Executive Vice President, Worldwide Chairman, Consumer Health
Paul Stoffels

Paul Stoffels

Vice Chairman of the Executive Committee and Chief Scientific Officer
Show more

Johnson & Johnson Office Locations

Johnson & Johnson has offices in New Brunswick, Jacksonville, Lancaster, Piscataway and in 66 other locations
New Brunswick, NJ, US (HQ)
1 Johnson And Johnson Plaza
Jacksonville, FL, US
7500 Centurion Pkwy N
Lancaster, PA, US
1838 Colonial Village Ln
Piscataway, NJ, US
425 NJ-18
Buenos Aires, AR
Mendoza 1259
Chippendale, AU
5 Broadway
Show all (73)

Johnson & Johnson Financials and Metrics

Johnson & Johnson Revenue

Embed Graph
View revenue for all periods
Johnson & Johnson's revenue was reported to be $82.06 b in FY, 2019 which is a 0.6% increase from the previous period.
USD

Revenue (Q3, 2020)

21.1b

Gross profit (Q3, 2020)

14.1b

Gross profit margin (Q3, 2020), %

66.9%

Net income (Q3, 2020)

3.6b

Market capitalization (19-Feb-2021)

429.1b

Closing stock price (19-Feb-2021)

163.0

Cash (27-Sept-2020)

19.0b

EV

447.8b
Johnson & Johnson's current market capitalization is $429.1 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

76.5b81.6b82.1b

Revenue growth, %

6%7%1%

Cost of goods sold

25.4b27.1b27.6b

Gross profit

51.1b54.5b54.5b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

17.8b18.8b19.7b20.0b20.8b20.3b20.0b20.6b20.7b20.7b18.3b21.1b

Cost of goods sold

5.4b5.8b6.9b6.6b6.9b6.6b6.6b6.9b6.9b7.1b6.6b7.0b

Gross profit

12.4b13.0b12.7b13.4b13.9b13.8b13.4b13.6b13.9b13.6b11.8b14.1b

Gross profit Margin, %

70%69%65%67%67%68%67%66%67%66%64%67%
show all
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

17.8b18.1b17.3b

Accounts Receivable

13.5b14.1b14.5b

Prepaid Expenses

2.5b2.7b2.4b

Inventories

8.8b8.6b9.0b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

20.9b12.6b15.7b14.6b17.6b16.1b14.7b14.4b16.2b15.5b11.2b19.0b

Accounts Receivable

12.3b13.3b13.2b14.2b14.1b14.0b14.1b14.7b14.8b14.9b14.6b14.6b

Prepaid Expenses

2.8b3.0b2.9b2.6b2.6b2.9b2.6b2.4b2.2b2.4b2.6b2.5b

Inventories

8.9b9.7b9.5b9.0b8.8b8.7b9.1b9.3b9.2b8.9b9.4b9.6b
show all
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

1.3b15.3b15.1b

Depreciation and Amortization

5.6b6.9b7.0b

Inventories

581.0m(644.0m)(277.0m)

Accounts Payable

2.7b4.0b4.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

4.4b8.2b12.0b4.4b8.3b12.3b3.7b9.4b11.1b5.8b9.4b13.0b

Depreciation and Amortization

912.0m2.1b3.8b1.7b3.5b5.2b1.8b3.5b5.2b1.7b3.5b5.3b

Inventories

(368.0m)(421.0m)(193.0m)(322.0m)(491.0m)(777.0m)(369.0m)(423.0m)(424.0m)(159.0m)(637.0m)(784.0m)

Accounts Payable

(2.0b)(1.2b)339.0m(1.7b)(49.0m)731.0m(1.8b)(444.0m)2.3b(2.5b)(2.3b)(119.0m)
show all
USDQ1, 2018

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2.1 x
Show all financial metrics

Johnson & Johnson Operating Metrics

FY, 2016FY, 2017Jun, 2018FY, 2018FY, 2019

Manufacturing Facilities

119 125 111 97

Countries

60 60 60

Distribution Centers

350

Suppliers

3.50 k
Show all operating metrics

Johnson & Johnson Acquisitions / Subsidiaries

Company NameDateDeal Size
Momenta PharmaceuticalsAugust 19, 2020$6.50 b
TARIS BiomedicalDecember 20, 2019
Verb SurgicalDecember 20, 2019
Auris HealthJanuary 23, 2019$3.40 b
Ci:z HoldingsOctober 23, 2018$2.10 b
Zarbee's NaturalsJuly 27, 2018
OrthotaxyFebruary 20, 2018
Actelion PharmaceuticalsJanuary 26, 2017$30 b
Abott Medical OpticsSeptember 16, 2016$4.33 b
Vogue InternationalJune 02, 2016$3.30 b
Show more

Johnson & Johnson Revenue Breakdown

Embed Graph

Johnson & Johnson revenue breakdown by business segment: 31.6% from Medical Devices, 51.4% from Pharmaceutical and 16.9% from Consumer

Johnson & Johnson revenue breakdown by geographic segment: 19.0% from Asia-Pacific, Africa, 7.2% from Western Hemisphere excluding US, 22.5% from Europe and 51.3% from United States

Human Capital Metrics

Embed Graph
Show all human capital metrics

Johnson & Johnson Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

Learn more about our premium products
SecurityScorecard logo

Johnson & Johnson Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

Learn more about our premium products
CSRHub logo

Johnson & Johnson Online and Social Media Presence

Johnson & Johnson's Trends

Embed Graph

Johnson & Johnson Company Culture

  • Overall Culture

    C+

    72/100

  • CEO Rating

    D-

    62/100

  • Compensation

    D

    54/100

Learn more on Comparably

Johnson & Johnson News and Updates

February 10, 2021

South Africa Abandons Oxford-AstraZeneca Covid-19 Vaccine In Favor Of Unapproved Johnson & Johnson Shot

The significant policy change is based on a small study that has not undergone peer review and did not evaluate the vaccine’s protection against severe disease, a key metric of success.
February 09, 2021

Key Words: Expect to get COVID-19 shots for years to come, Johnson & Johnson CEO says

In an interview with CNBC, CEO Alex Gorsky said mutations of the coronavirus will necessitate changes to vaccines, much like annual flu shots.
February 09, 2021

When Will The Johnson & Johnson Covid-19 Coronavirus Vaccine Be Approved?

The FDA committee will meet on February 26 to make their recommendation about the Johnson & Johnson Covid-19 vaccine emergency use authorization (EUA) application. But apparently this is not fast enough for everyone
February 04, 2021

Johnson & Johnson submits application for COVID vaccine candidate to FDA

Johnson & Johnson submits application for COVID vaccine candidate to FDA
February 04, 2021

Johnson & Johnson requests emergency authorization from FDA for Covid vaccine

If J&J's application is approved, it would be the third Covid vaccine authorized for emergency use in the U.S. behind those developed by Pfizer-BioNTech and Moderna.
February 02, 2021

Johnson & Johnson Vaccine’s 66% Efficacy Figure Is Better Than It Looks

Johnson & Johnson announced that its single-shot Covid-19 vaccine was 66% effective in preventing moderate and severe cases of Covid-19 in its global phase 3 trials. Efficacy varied by region, with the shot proving 72% effective in the U.S., 66% effective in Latin America, and around 57% effecti…
Show more

Johnson & Johnson Blogs

February 24, 2021

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months

February 24, 2021

Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021

February 19, 2021

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

February 16, 2021

Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

February 08, 2021

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination

February 08, 2021

Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer

Show more

 Johnson & Johnson Frequently Asked Questions

  • When was Johnson & Johnson founded?

    Johnson & Johnson was founded in 1886.

  • Who are Johnson & Johnson key executives?

    Johnson & Johnson's key executives are Alex Gorsky, Joaquin Duato and Peter Fasolo.

  • How many employees does Johnson & Johnson have?

    Johnson & Johnson has 132,200 employees.

  • What is Johnson & Johnson revenue?

    Latest Johnson & Johnson annual revenue is $82.1 b.

  • What is Johnson & Johnson revenue per employee?

    Latest Johnson & Johnson revenue per employee is $620.7 k.

  • Who are Johnson & Johnson competitors?

    Competitors of Johnson & Johnson include Bayer, Pfizer and Procter & Gamble.

  • Where is Johnson & Johnson headquarters?

    Johnson & Johnson headquarters is located at 1 Johnson And Johnson Plaza, New Brunswick.

  • Where are Johnson & Johnson offices?

    Johnson & Johnson has offices in New Brunswick, Jacksonville, Lancaster, Piscataway and in 66 other locations.

  • How many offices does Johnson & Johnson have?

    Johnson & Johnson has 73 offices.